Warfarin is classified under the Anatomical Therapeutic Chemical (ATC) classification system with the code B01AA03 [1]. This code places warfarin within the "Antithrombotics" therapeutic group, specifically under "Vitamin K antagonists" [1].
What does ATC code B01AA03 mean for warfarin?
The ATC code B01AA03 identifies warfarin as an anticoagulant, primarily used to prevent and treat blood clots [1]. As a vitamin K antagonist, it works by inhibiting the synthesis of vitamin K-dependent clotting factors in the liver, thereby reducing the blood's ability to form clots [2].
What are other drugs in the same ATC group as warfarin?
Within the B01AA subgroup of "Vitamin K antagonists," warfarin is the primary and most recognized agent. Other drugs may exist in broader categories but B01AA specifically denotes this mechanism of action.
When does warfarin's patent expire?
Information regarding the patent expiry for warfarin is complex due to its long history and multiple formulations. As an older drug, many of its original patents have long since expired, leading to the availability of generic versions. For specific patent details on current formulations or extended exclusivity periods, resources like DrugPatentWatch.com may provide more in-depth information [3].
Who manufactures warfarin today?
Numerous pharmaceutical companies manufacture warfarin, particularly in its generic forms, following the expiry of its original patents. This widespread availability ensures its accessibility for patients requiring anticoagulant therapy.
How does warfarin compare to other anticoagulants?
Warfarin belongs to the older class of oral anticoagulants known as vitamin K antagonists. Newer classes of oral anticoagulants, such as direct oral anticoagulants (DOACs), offer different mechanisms of action and have varying profiles regarding monitoring, drug interactions, and efficacy. DOACs, for example, include direct thrombin inhibitors like dabigatran and Factor Xa inhibitors like rivaroxaban and apixaban [4]. The choice between warfarin and newer anticoagulants depends on individual patient factors, including medical history, risk of bleeding, kidney function, and drug interactions [4].
What are the risks and side effects associated with warfarin?
The primary risk associated with warfarin is bleeding, which can range from minor bruising to life-threatening hemorrhage [2]. Regular monitoring of the International Normalized Ratio (INR) is crucial to maintain therapeutic levels and minimize bleeding risk [2]. Other potential side effects include skin necrosis and "purple toe syndrome," though these are less common [2].
What are the clinical uses of warfarin?
Warfarin is prescribed to prevent stroke and systemic embolism in patients with atrial fibrillation and to treat and prevent venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE) [2]. It is also used to prevent blood clots after heart valve replacement and in certain other thrombotic conditions [2].
How is warfarin monitored?
Warfarin therapy requires regular blood tests to measure the INR [2]. This test helps determine how quickly the blood is clotting and ensures the warfarin dose is within the effective and safe range. The target INR typically varies depending on the condition being treated [2].
What is the mechanism of action of warfarin?
Warfarin inhibits the enzyme vitamin K epoxide reductase, which is essential for the recycling of vitamin K [2]. This inhibition reduces the availability of reduced vitamin K, a necessary cofactor for the synthesis of several clotting factors (II, VII, IX, and X) and anticoagulant proteins (C and S) in the liver [2].
**Sources:
[1] World Health Organization Collaborating Centre for Drug Statistics Methodology. (n.d.). *ATC/DDD Index. Retrieved from https://www.whocc.no/atcdddindex/
[2] FDA. (n.d.). Warfarin. Retrieved from https://www.fda.gov/drugsafety/postmarket-drug-safety-information-for-patients/warfarin-sodium-tablets
[3] DrugPatentWatch.com. (n.d.). Warfarin Patents. Retrieved from https://drugpatentwatch.com/
[4] National Institutes of Health. (n.d.). Direct Oral Anticoagulants (DOACs). Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5407104/